---
title: "Savara Q4 net loss widens as expenses rise"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279041569.md"
datetime: "2026-03-13T12:15:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279041569.md)
  - [en](https://longbridge.com/en/news/279041569.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279041569.md)
---

# Savara Q4 net loss widens as expenses rise

)

Overview

-   US rare disease drug developer’s Q4 net loss widened yr/yr as expenses rose
-   General and administrative expenses increased due to workforce expansion and commercial planning
-   Company achieved key regulatory milestones for MOLBREEVI in US and Europe

Outlook

-   Savara expects FDA PDUFA decision on MOLBREEVI by August 22, 2026

Result Drivers

-   REGULATORY COSTS - Higher research and development expenses were primarily due to regulatory affairs and quality assurance activities related to the MOLBREEVI BLA submission
-   COMMERCIAL PLANNING - General and administrative expenses rose due to workforce expansion and commercial activities ahead of potential MOLBREEVI launch Company press release:

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

### Q4 EPS -$0.13

Q4 Net -$32.24

Income mln

### Q4 -$33.42

Income mln

from

Operatio

ns

### Q4 $33.42

Operatin mln

g

Expenses

Analyst Coverage

-   The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 8 “strong buy” or “buy”, no “hold” and no “sell” or “strong sell”
-   The average consensus recommendation for the biotechnology & medical research peer group is “buy”
-   Wall Street’s median 12-month price target for Savara Inc is $10.25, about 92.7% above its March 12 closing price of $5.32 For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

### Related Stocks

- [SVRA.US](https://longbridge.com/en/quote/SVRA.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)

## Related News & Research

- [BUZZ-Precision BioSciences up as hepatitis B gene‑editing trial expands in Europe](https://longbridge.com/en/news/282832865.md)
- [BUZZ-Street View: Analysts upbeat on Revolution pancreatic cancer drug](https://longbridge.com/en/news/282702171.md)
- [Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform](https://longbridge.com/en/news/282587297.md)
- [FDA Rejection Sparks Questions On Replimune Drug Approval Path](https://longbridge.com/en/news/282577359.md)
- [Revolution Medicines' experimental cancer pill helps improve survival in late-stage study](https://longbridge.com/en/news/282540793.md)